We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
In the latest close session, Zoetis (ZTS - Free Report) was down 1.32% at $146.25. The stock fell short of the S&P 500, which registered a gain of 0.47% for the day. On the other hand, the Dow registered a gain of 0.11%, and the technology-centric Nasdaq increased by 0.94%.
Heading into today, shares of the animal health company had lost 3.83% over the past month, lagging the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32%.
The investment community will be closely monitoring the performance of Zoetis in its forthcoming earnings report. It is anticipated that the company will report an EPS of $1.64, marking a 3.8% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.43 billion, indicating a 1.56% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.34 per share and revenue of $9.51 billion, which would represent changes of +7.09% and +2.79%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Zoetis. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Zoetis currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Zoetis has a Forward P/E ratio of 23.38 right now. This represents a premium compared to its industry average Forward P/E of 15.43.
Investors should also note that ZTS has a PEG ratio of 2.39 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Drugs industry had an average PEG ratio of 1.38 as trading concluded yesterday.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
In the latest close session, Zoetis (ZTS - Free Report) was down 1.32% at $146.25. The stock fell short of the S&P 500, which registered a gain of 0.47% for the day. On the other hand, the Dow registered a gain of 0.11%, and the technology-centric Nasdaq increased by 0.94%.
Heading into today, shares of the animal health company had lost 3.83% over the past month, lagging the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32%.
The investment community will be closely monitoring the performance of Zoetis in its forthcoming earnings report. It is anticipated that the company will report an EPS of $1.64, marking a 3.8% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.43 billion, indicating a 1.56% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.34 per share and revenue of $9.51 billion, which would represent changes of +7.09% and +2.79%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Zoetis. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Zoetis currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Zoetis has a Forward P/E ratio of 23.38 right now. This represents a premium compared to its industry average Forward P/E of 15.43.
Investors should also note that ZTS has a PEG ratio of 2.39 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Drugs industry had an average PEG ratio of 1.38 as trading concluded yesterday.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.